• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高科技医学的伦理、政治和社会层面:曙光与关怀。

Ethical, political, and social aspects of high-technology medicine: Eos and care.

作者信息

Zamperetti Nereo, Bellomo Rinaldo, Dan Maurizio, Ronco Claudio

机构信息

San Bortolo Hospital, Department of Anesthesia and Intensive Care Medicine, Via Rodolfi 37, 36100 Vicenza, Italy.

出版信息

Intensive Care Med. 2006 Jun;32(6):830-5. doi: 10.1007/s00134-006-0155-0. Epub 2006 Apr 14.

DOI:10.1007/s00134-006-0155-0
PMID:16614809
Abstract

OBJECTIVE

We discuss biosocial aspects of high-technology medicine (HTM) to provide a global view of the current model of medicine in the developed world and its consequences.

METHODS

We analyze changes in the concept of death and in the use and cost of HTM. The consequences of HTM on the delivery of basic medical care within and among countries are discussed. Concepts derived from Greek mythology are used to illustrate the problems associated with HTM.

RESULTS

HTM can be extremely effective in individual cases, but it poses important bioethical and biosocial problems. A major problem is related to the possibility of manipulating the process of dying and the consequent alteration in the social concept of death, which, if not carefully regulated, risks transforming medicine into an expensive way of pursuing pointless dreams of immortality (myth of Eos). Another problem is related to the extraordinary amount of resources necessary for HTM. This model of medicine (which is practiced daily) has limited sustainability, can work only in highly developed countries, may contribute to unequal access to health care, and has negligible positive impact on global health and survival.

CONCLUSIONS

HTM poses very important biosocial questions that need to be addressed in a wider and transparent debate, in the best interest of society and HTM as well.

摘要

目的

我们探讨高科技医学(HTM)的生物社会层面,以全面了解发达国家当前的医学模式及其后果。

方法

我们分析死亡概念以及高科技医学的使用和成本的变化。讨论了高科技医学对国家内部和国家之间基本医疗服务提供的影响。源自希腊神话的概念被用来阐释与高科技医学相关的问题。

结果

高科技医学在个别案例中可能极其有效,但它引发了重要的生物伦理和生物社会问题。一个主要问题与操纵死亡过程的可能性以及随之而来的社会死亡概念的改变有关,如果不加以谨慎规范,存在将医学转变为追求无意义永生梦想(厄俄斯神话)的昂贵方式的风险。另一个问题与高科技医学所需的大量资源有关。这种医学模式(每天都在实践)可持续性有限,只能在高度发达国家开展,可能导致医疗保健获取的不平等,并且对全球健康和生存的积极影响微不足道。

结论

高科技医学提出了非常重要的生物社会问题,需要在更广泛和透明的辩论中加以解决,这也是为了社会和高科技医学的最大利益。

相似文献

1
Ethical, political, and social aspects of high-technology medicine: Eos and care.高科技医学的伦理、政治和社会层面:曙光与关怀。
Intensive Care Med. 2006 Jun;32(6):830-5. doi: 10.1007/s00134-006-0155-0. Epub 2006 Apr 14.
2
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
3
End of life in the Intensive Care Unit.重症监护病房的生命终末期。
Minerva Anestesiol. 2010 Jul;76(7):541-7.
4
Tuberculosis结核病
5
Policy and ethical issues in applying medical biotechnology in developing countries.在发展中国家应用医学生物技术中的政策与伦理问题。
Med Sci Monit. 2003 Feb;9(2):RA49-54.
6
3D Bioprinting Technology: Scientific Aspects and Ethical Issues.3D 生物打印技术:科学方面和伦理问题。
Sci Eng Ethics. 2018 Apr;24(2):335-348. doi: 10.1007/s11948-017-9918-y. Epub 2017 Jun 28.
7
Implementing primary health care: some problems of creating national programmes.实施初级卫生保健:创建国家项目的一些问题。
Trop Doct. 1984 Jul;14(3):108-13. doi: 10.1177/004947558401400304.
8
Different ways of problematising biotechnology--and what it means for technology governance.对生物技术进行问题化处理的不同方式——以及这对技术治理意味着什么。
Public Underst Sci. 2015 Jul;24(5):516-32. doi: 10.1177/0963662514539074. Epub 2014 Jun 24.
9
[The origin of informed consent].[知情同意的起源]
Acta Otorhinolaryngol Ital. 2005 Oct;25(5):312-27.
10
New genetics, new ethics? Globalisation and its discontents.新遗传学,新伦理?全球化及其不满。
Health Risk Soc. 2001 Nov;3(3):245-59. doi: 10.1080/13698570120079868.

引用本文的文献

1
Coming together to care for the dying in India.齐聚一堂关怀印度的临终者。
Indian J Crit Care Med. 2014 Sep;18(9):560-2. doi: 10.4103/0972-5229.140139.

本文引用的文献

1
Activated protein C: do more survive?活化蛋白C:更多患者能存活吗?
Intensive Care Med. 2005 Dec;31(12):1624-6. doi: 10.1007/s00134-005-2829-4. Epub 2005 Oct 15.
2
G8 2005: a missed opportunity for global health.2005年八国集团峰会:全球健康的一个错失的机遇。
Lancet. 2005;366(9481):177.
3
Quarter of US women postpone or forego treatment because of cost.四分之一的美国女性因费用问题推迟或放弃治疗。
BMJ. 2005 Jul 16;331(7509):130. doi: 10.1136/bmj.331.7509.130-e.
4
Perinatal mortality in developing countries.发展中国家的围产期死亡率。
N Engl J Med. 2005 May 19;352(20):2047-8. doi: 10.1056/NEJMp058032.
5
Surviving sepsis-but for how long?脓毒症幸存者——但能存活多久?
Intensive Care Med. 2005 Feb;31(2):171-3. doi: 10.1007/s00134-004-2546-4. Epub 2005 Jan 28.
6
Will ethical requirements bring critical care research to a halt?伦理要求会使重症监护研究停滞不前吗?
Intensive Care Med. 2005 Mar;31(3):338-44. doi: 10.1007/s00134-004-2480-5. Epub 2004 Nov 4.
7
Withholding and withdrawing life-support therapy in an Emergency Department: prospective survey.急诊科生命支持治疗的 withhold 与 withdraw:前瞻性调查
Intensive Care Med. 2004 Dec;30(12):2216-21. doi: 10.1007/s00134-004-2475-2. Epub 2004 Oct 29.
8
Protecting the uninsured.保护未参保者。
N Engl J Med. 2004 Oct 7;351(15):1479-81. doi: 10.1056/NEJMp048160.
9
Making health systems more equitable.使卫生系统更具公平性。
Lancet. 2004;364(9441):1273-80. doi: 10.1016/S0140-6736(04)17145-6.
10
Bioethics, health, and inequality.生物伦理学、健康与不平等。
Lancet. 2004;364(9439):1086-91. doi: 10.1016/S0140-6736(04)17066-9.